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Abstract
In mouse models of acute motor axonal neuropathy, anti-ganglioside antibodies
(AGAbs) bind to motor axons, notably the distal nerve, and activate the complement
cascade. While complement activation is well studied in this model, the role of
inflammatory cells is unknown. Herein we aimed to investigate the contribution of
phagocytic cells including macrophages, neutrophils and perisynaptic Schwann cells
(pSCs) to distal nerve pathology. To observe this, we first created a subacute injury
model of sufficient duration to allow inflammatory cell recruitment. Mice were
injected intraperitoneally with an anti-GD1b monoclonal antibody that binds strongly
to mouse motor nerve axons. Subsequently, mice received normal human serum as a
source of complement. Dosing was titrated to allow humane survival of mice over a
period of 3 days, yet still induce the characteristic neurological impairment. Behav-
iour and pathology were assessed in vivo using whole-body plethysmography and
post-sacrifice by immunofluorescence and flow cytometry. ex vivo nerve-muscle
preparations were used to investigate the acute phagocytic role of pSCs following
distal nerve injury. Following complement activation at distal intramuscular nerve
sites in the diaphragm macrophage localisation or numbers are not altered, nor do
they shift to a pro- or anti-inflammatory phenotype. Similarly, neutrophils are not sig-
nificantly recruited. Instead, ex vivo nerve-muscle preparations exposed to AGAb
plus complement reveal that pSCs rapidly become phagocytic and engulf axonal
debris. These data suggest that pSCs, rather than inflammatory cells, are the major
cellular vehicle for axonal debris clearance following distal nerve injury, in contrast to
larger nerve bundles where macrophage-mediated clearance predominates.
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1 | INTRODUCTION
In the autoimmune neuropathy, Guillain-Barré syndrome (GBS), injury
to peripheral nerves is in part caused by autoantibodies activating the
complement cascade. In the acute motor axonal neuropathy (AMAN)
form of GBS, the autoantibody targets are neural gangliosides, and are
found with high frequency in AMAN patient sera. Evidence from
patient autopsy tissue indicates complement activation occurs in GBS
patients manifested by the deposition of complement products on
axonal membranes and the presence of circulating terminal comple-
ment product MAC.1,2 In addition to this, macrophage infiltration into
the periaxonal space has been shown to be an early feature in spinal
root analysis of fatal cases AMAN.3
In rabbit models of GBS, active immunisation with Campylobacter
jejuni derived GM1-like lipooligosaccharides or GM1 ganglioside cau-
ses delayed (35-57 days) flaccid paralysis corresponding with an
increase in serum reactivity to GM1 ganglioside. As observed in rabbit
sciatic nerve, complement proteins are deposited at nodes of Ranvier,
macrophages invade the periaxonal space and Wallerian-like axon
degeneration occurs.4,5 In this model, there is evidence that the pres-
ence of macrophages may be associated rather with the recovery
phase than the induction of injury.6
Our existing mouse models of GBS have focused on hyperacute
injury (<24 hours), in which the injection of monoclonal anti-
ganglioside antibodies (AGAbs), followed by normal human serum
(NHS) via intraperitoneal routes results in rapid onset respiratory fail-
ure (<4 hours following NHS as a supplementary complement source),
accompanied by prominent distal motor nerve terminal and pre-
terminal nodal injury. This injury is maximally manifested in the intra-
muscular nerve fibres of the diaphragm muscle, due to its close prox-
imity to the intraperitoneal injection site.7,8 From these models, we
have been able to monitor the hyperacute effects of AGAb and
complement-mediated axonal injury, demonstrating the loss of struc-
tural proteins such as axonal neurofilament (NFil), in parallel with the
resultant deficits in respiratory function. We have also used these
models to demonstrate the benefits of complement inhibition as a
potential therapeutic pathway in GBS.
In the above mouse model of GBS, the formation of the MAC
pore is essential for the acute structural and functional damage to
axons. The prominence and severity of the MAC pore injury has pre-
cluded investigation of other mechanisms for complement-mediated
injury. For example, complement activation might be expected to
result in the release of anaphylatoxins C3a and C5a, which are chemo-
attractants for phagocytic immune cells, including neutrophils and
macrophages9 and can influence these cells to produce harmful, pro-
inflammatory cytokines.10 In addition, the complement products C3b
iC3b and C3d are deposited on the membrane and opsonize it for
phagocytosis.9
In the case of distal motor nerve injury, the role of perisynaptic
Schwann cells (pSCs) which overlie the motor nerve terminal and con-
stitute one third of the neuromuscular junction (NMJ) needs consider-
ation. These cells have multiple functions including monitoring and
regulation of synaptic transmission,11-13 formation and maintenance
of the NMJ14-16 and a phagocytic response to axonal injury.17,18 Fol-
lowing distal axonal injury induced by both laser axotomy (ex vivo)
and alpha-latrotoxin (in vivo), pSCs have also been shown to clear
motor nerve terminal debris, much like their myelinating counterparts.
Indeed recent studies have demonstrated that in a latrotoxin injury of
the motor nerve terminal, which results in a calpain-driven injury to
the axon similar to our GBS mouse models,19,20 pSCs not only become
activated but also show evidence of debris clearance.21 However, lon-
ger term studies into the contribution of other phagocytic cells have
not been investigated. In separate studies in which we have targeted
pSCs for acute autoantibody attack, we have explored the bipartite
relationship between distal axon and pSCs22; however, in the current
AGAb-mediated model, we describe herein, pSCs are not directly
targeted and this is not considered further.
We recently investigated the acute effects of an anti-C1q anti-
body on AGAb and complement-mediated motor nerve terminal injury
using our current mouse model. At this early timepoint, at which we
observe acute complement-mediated changes (6 hours), there was an
insignificant effect on immune cell infiltration within the vicinity of
the complement activation.8 This was unsurprising considering the
window between complement activation and tissue analysis was only
6 hours, whereas macrophage recruitment occurs over 3 to
7 days.23-25
To investigate the consequences of our AGAb and complement-
mediated distal nerve injury at timepoints greater than 6 hours, we
herein describe a model whereby mice survive beyond this critical
window of injury severity. We investigate the contributions of neutro-
phils, macrophages and pSCs following injury to this specialised site,
which may influence the rapid recovery seen in some cases of
AMAN.26
2 | METHODS
2.1 | Mice
Male and female MacGreen mice (kindly provided by Prof. G. Graham,
University of Glasgow) were used between 4 and 5 weeks of age for
in vivo studies. These mice express enhanced green fluorescent pro-
tein (eGFP) driven by Csf1r gene resulting in expression in mononu-
clear phagocytes such as macrophages and monocytes.27 For ex vivo
studies, B6.Cg-Tg(Thy1-CFP/S100B-GFP) transgenic mice were used.
These mice express cyan fluorescent protein (CFP) and green fluores-
cent protein (GFP) in their axons and Schwann cells, respectively.28,29
All procedures were conducted under licence by the UK's Home
Office and complied with the Animals (Scientific Procedures) Act
of 1986.
2.2 | Study design
Mice were assigned to study groups using a random team generator.
All samples were analysed blinded. Sample size was estimated using
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an a priori power analysis with G*Power software (v 3.1.9.2), using an
effect size of 4.03, an alpha error probability of .05, and a power
of 0.8.
2.3 | AGAbs and NHS
Anti-GD1b IgG antibody (MOG-1) was generated by immunisation of
ganglioside-deficient mice with ganglioside liposomes as described
previously.30,31 The properties of this antibody have been reported.32
Anti-GD1b antibody binds strongly to neuronal tissue in mice, without
any notable binding to glial cells. NHS as a source of human comple-
ment was taken from a single donor and stored in aliquots at −80C.
2.4 | Ex vivo injury model
Triangularis sterni (TS) muscle from B6.Cg-Tg(Thy1-CFP/S100B-GFP)
transgenic mice was dissected and mounted in oxygenated Ringer's
solution (116 mM NaCl, 4.5 mM KCl, 23 mM NaHCO3, 1 mM
NaH2PO4, 11 mM glucose, 1 mM MgCl2, and 2 mM CaCl2). Muscles
were labelled with AGAb (100 mg/mL) for 1 hour at 4C then washed
and 40% NHS added for 10 minutes to cause an acute injury to motor
nerve terminals. NHS was washed off and preparations were kept at
room temperature in Ringer's for a further 4 hours to allow injury to
develop. Preparations were fixed in 4% PFA at 4C for 20 minutes
before washing for 10 minutes each in PBS, 0.1 M glycine and PBS
again. Preparations were stained with rabbit anti-mouse synapsin
(Abcam, 1/100) overnight in PBS containing 3% normal goat serum
(NGS) and 0.5% Triton-X100. In cytochalasin D (CytD)-treated group,
CytD (Sigma, 5 μg/mL) was added for 1 hour prior to the addition of
antibody.
2.5 | In vivo injury model
MacGreen mice were injected intraperitoneally with 40 mg/kg of the
anti-GD1b antibody, MOG1. This was followed 16 hours later by
intraperitoneal injection of NHS (30 μL/g). The current MOG1 dose is
a ~33% reduction compared with our previously published models.8
Control mice were either completely naïve mice, or mice which
received NHS with no previous antibody injection (NHS only). Mice
were either culled at 6 hours post-NHS injection (to monitor for acute
changes at the distal axon) or days 1 or 3 post-NHS injection to assess
neutrophil or macrophage recruitment respectively.
2.6 | Plethysmography
Whole-body plethysmography was performed (Electro-Medical Mea-
surement systems, Hampshire, UK) to measure changes in tidal vol-
ume as a readout of diaphragm function. Mice were habituated to the
plethysmography chambers 1 to 3 days prior to the study's start.
Recordings were taken before injection of antibody and at 6, 24, and
72 hours post-injection of NHS. On each occasion, mice were left for
30 to 45 minutes to acclimatise to the chambers before recordings
began.
2.7 | Immunofluorescence staining
To assess the presence of C3c, MAC, NFil, and IgG3 at NMJs, dia-
phragms were snap frozen and stored at −80C until
cryosectioned. Longitudinal sections of 8 or 15 μm were collected
onto Starfrost slides and stored at −20C. For C3c and IgG3, sec-
tions were incubated in staining solution (PBS with 3% NGS) with
alpha-bungarotoxin (BTx)-555 along with either mouse anti-human
C3c-FITC (10 μg/mL in PBS) or anti-mouse IgG3-FITC (3.33 μg/mL
in PBS) for 2 hours at room temperature. For MAC, tissue was
incubated overnight in PBS with 3% NGS containing anti-human
C5b-9 (2.375 μg/mL, Dako). For NFil staining, tissue was incubated
in BTx for 1 hour at 4C, rinsed, immersed in freezing ethanol at
−20C for 10 minutes before washing in PBS then incubating
overnight in SMI31, an anti-phosphorylated NFil heavy antibody
(1/1500, Biolegend). Secondary antibodies were added next day for
2 hours at room temperature.
For macrophage quantitation, diaphragms were post-fixed at 4C
in 4% PFA for 1 hour then sunk in sucrose and stored at −80C. Sec-
tions were cut at 15 μm and stored at −20C then stained with BTx-
555 (1/750) and mounted in Vectashield mounting media with DAPI.
For neutrophils, fixed diaphragm was incubated with neutrophil
marker antibody (NIMP-R14 sc-59 338, Santa Cruz Biotechnology) at
1:50 overnight in staining solution before secondary addition. All
staining was done in either duplicate or triplicate.
2.8 | Flow cytometry
For flow cytometry, diaphragms were digested for 1 hour in 5 mL
0.2% collagenase II (MP Biomedicals) at 37C. Collagenase was
inactivated with addition of FACS buffer (2% FCS in dPBS with 2 mM
EDTA). Tissue was filtered through a 70 μm, strainer and washed (cen-
trifugation at 400g at 4C for 5 minutes). Lysis buffer was added for
1 minute to remove red blood cells and washed 2x with FACS buffer.
Cell viability was determined using Fixable Viability Dye eFluor
780 (eBioscience, UK) at a dilution of 1/1000 in FACS buffer for
20 minutes at 4C. Cells were washed and incubated with
fluorophore-conjugated antibodies at 1/200 dilution in Fc block (anti-
mouse CD16/32, BioLegend, in FACS buffer) for 20 minutes at 4C.
Antibodies used were CD45-PE (eBioscience, clone 30-F11), CD11b-
APC (BD pharminogen, clone M1/70), Ly6G-PerCPCy5.5
(eBioscience, clone1A8-Ly6g), F4/80-eFluor 450 (eBioscience, clone
BM8), NOS-PECy7 (eBioscience, clone CXNFT), and CD206-AF
700 (eBioscience, clone C068C2). Data were acquired using an LSRII
flow cytometer (BD Biosciences) and analysed using FlowJo software
(TreeStar version 7.6.5).
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2.9 | Image acquisition and quantitation
For quantification of C3c, MAC, NFil, and IgG3 presence at NMJs,
images were captured using a Zeiss LSM880 microscope. The mean
intensity of staining overlying the BTx area (to delineate the NMJ) was
measured in each case. Analysis was performed using the Fiji distribution
of ImageJ software (version 1.52b).33 For macrophage counts, images
with BTx signal were captured using a Zeiss AxioImagerZ1 microscope
and the number of macrophages (denoted by positive endogenous eGFP
signal with DAPI+ve nucleus) in the entire field of view (FOV), within
50 μm of an NMJ and overlying NMJs were counted manually. For neu-
trophil quantification, the number of cells positive for NIMP-R14+ve
cells with DAPI+ve nuclei was counted in the same manner. In both
types of quantification, images were captured and analysed blinded using
the same rater for all like analysis. Fifteen images of each duplicate or
triplicate were captured for each immunostained tissue section.
3 | RESULTS
3.1 | Low dose model of distal nerve injury
provides sufficient injury while allowing mouse
survival
In our previous studies, the contribution of macrophages could not be
investigated in our distal motor nerve terminal injury due to the
severe nature of the respiratory injury superseding the humane end-
point for in vivo experimentation.8 In order to investigate recruitment
of macrophages following immune-mediate distal nerve terminal
injury, the doses of AGAb and complement were reduced in compari-
son with our previous studies.7,8 Otherwise, the protocol remained
similar to previous studies (Figure 1A). This dose reduction allowed
the survival of mice beyond the 6-hour timepoint where robust com-
plement activation and loss of NFil is seen but macrophage recruit-
ment is not.8 Mice receiving antibody and complement still displayed
the typical phenotype of impaired respiration with wasp-like abdo-
men, indicating the diaphragm is paralysed. Whole-body plethysmog-
raphy also showed a reduced tidal volume in comparison to control
mice, indicating an observable functional deficit (Figure 1B). Morpho-
logically, significant amounts of complement C3c were deposited over
NMJs compared with controls (Figure 1C,D). Similarly, significant
MAC deposition was seen overlying the NMJ, corresponding with a
significant loss in NFil heavy protein, indicating axonal injury
(Figure 1C,D). Overall, this demonstrates a significant injury to the dis-
tal motor nerves was still achievable with lower doses of AGAb and
complement. However, mice were able to survive past the 6-hour
post-NHS timepoint. By the following morning (day 1), the pinched
abdomen phenotype had improved and continued to recover over the
subsequent days. Prior to sacrifice on day 3, their abdominal profile
and tidal volume was comparable to controls. Upon sacrifice at this
timepoint, NFil and MAC immunostaining was comparable between
groups with infrequent NMJs from Ab + NHS-treated mice displaying
low levels of MAC (Figure 1E).
3.2 | Neutrophils and macrophages are not
recruited following AGAb and complement-mediated
distal nerve injury
Having established a model whereby mice could humanely survive a
distal motor nerve Ab and complement-mediated nerve injury, we
examined whether immune cell recruitment occurs following such a
localised injury at this specialised site. By comparing tissue taken on
day 3 by flow cytometry, we found no difference in overall presence of
either neutrophils or macrophages in the diaphragm muscle (Figure 2A,
B). Furthermore, there were no differences in macrophages expressing
either anti-inflammatory (CD206) or pro-inflammatory (NOS) markers,
indicating no switch in phenotype of the resident tissue macrophages.
As the injury site is localised to the motor nerve terminal and distal
nerve, we also compared by immunofluorescence the presence of neu-
trophils and eGFP+ve macrophages within the proximity of the motor
nerve terminals at 1 and 3 days, respectively. Specifically, we sought
immune cells in the whole FOV, within 50 μm of the NMJ and overlying
the NMJ. While an increase in macrophages was seen compared to
naïve mice in all these categories, NHS-treated mice also showed
increased macrophage presence compared to naïve mice (Figure 2D,F).
Therefore, any increases were not due to specific complement activa-
tion at site of motor nerve terminal injury, but the general presence of
heterologous complement activation. Macrophages within the whole
FOV were also analysed for presence of NFil staining within their cell
bodies but no significant changes occurred between all three groups
(data not shown). Similar trends were observed in neutrophils numbers
at 1-day timepoint (Figure 2C,E). However, these data were not statisti-
cally different, even from naïve mice.
3.3 | pSCs phagocytose nerve terminal debris
following AGAb and complement-mediated distal
nerve injury
As we did not observe any changes in neutrophil or macrophage influx
to the diaphragm relating to complement activation at the distal
nerve, we investigated whether the consequences of AGAb and
complement-mediated injury may result in debris clearance by pSCs.
To analyse this, we used whole mount TS, ex vivo preparations from
B6.Cg-Tg(Thy1-CFP/S100B-GFP) mice exposed to the MOG1 anti-
GD1b AGAb to injure the axon. Following an initial AGAb and
complement-mediated injury, components of the axon were found
within pSC cell bodies after 4 hours (Figure 3A). In B6.Cg-Tg
(Thy1-CFP/S100B-GFP) transgenic mice, CFP which is expressed in
the axonal cytoplasm and is not a substrate of the protease calpain, is
found in large globules within the body of the GFP+ve pSCs. Four
hours after injury, synapsin, a vesicle-associated protein, is no longer
found in a distinct pattern along the inner surface of the axon as seen
in control-treated tissue. Instead, staining for synapsin becomes more
diffuse and is often found in the pSC body. These axon components
are found within vacuoles in the pSCs which do not appear in the
uninjured NHS-treated tissue.
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F IGURE 1 Lowered doses of anti-ganglioside antibody (AGAb) and complement allows sufficient injury to distal nerve while allowing survival
and recovery of injured mice. A, Protocol of model showing treatments given to mouse groups. B, Whole-body plethysmography (n = 4/group) of
AB + normal human serum (NHS)-treated mice showed measurable reduction in tidal volume within 6 hours of NHS treatment vs naïve mice.
After 24 hours, tidal volume was still affected but by 72 hours, it had returned to levels comparable with naive mice. NHS-treated mice showed
no difference vs naïve mice. C, Illustrative images show lack of C3c and MAC at neuromuscular junction (NMJs) of control mice while in Ab
+ NHS-treated mice C3c and MAC can be seen overlying the NMJ. This corresponds with a loss of neurofilament (NFil) staining at the NMJ. D,
Quantification of intensity of immunofluorescent staining for NFil, MAC, IgG3, and C3c overlying BTx signal. Ab + NHS-treated mice showed
significantly increased the presence of complement products C3c and MAC and significantly reduced NFil intensity. IgG3 was comparable
between Ab only and Ab + NHS-treated mice. E, At 3 days post-NHS, mice from all groups had comparable levels of MAC and NFil. * = P < .05,
** = P < .01, *** = P < .001, **** = P < .0001, one-way ANOVA with Tukey's multiple comparisons test
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To confirm that the presence of CFP and synapsin in the pSC cell
bodies resulted from phagocytosis of neuronal debris by the pSCs,
ex vivo nerve-muscle preparations were treated with CytD (which
prevents actin polymerisation and therefore phagocytosis) prior to
injury, then analysed for presence of components in the pSC cells
bodies (Figure 3B). Treatment with CytD decreased the frequency of
both CFP and synapsin presence in comparison to CytD-untreated
preparations.
F IGURE 2 Neutrophils and macrophages do not infiltrate following anti-ganglioside antibody (AGAb) and complement-mediated injury to the
distal nerve. A, Flow cytometry from mice survived for 3 days (n = 4 Ab + normal human serum (NHS) and NHS, n = 5 naive) showed no differences
in neutrophils or macrophage numbers in the diaphragm, nor any large switch to pro-inflammatory (NOS) or anti-inflammatory (CD206)
phenotype. B, Flow cytometry data were normalised to naïve mouse data. No differences were observed between NHS-treated and AB + NHS-
treated mice. High variability between mice was observed. C, Illustrative examples of neutrophil immunostaining from mouse diaphragms taken
1 day after NHS. D, Illustrative examples of enhanced green fluorescent protein (eGFP) (eGFP+ve) macrophages in mouse diaphragms taken 3 days
following NHS. E, Quantification of neutrophil data shows no significant changes in neutrophil numbers in close proximity to the neuromuscular
junction (NMJ). F, Quantification of macrophage numbers showed increases in macrophage numbers, but this was also seen in NHS only treated
animals. n = 4/group for immunofluorescence counts * = P < .05, ** = P < .01, one-way ANOVA with Tukey's multiple comparisons test
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4 | DISCUSSION
In AMAN patients, macrophages are known to infiltrate into the
periaxonal space in nerve roots and are thought to have pro- or anti-
inflammatory functions depending on the stage of disease. In our dis-
tal motor axonal injury model of GBS, we have never been able to
fully investigate the late cellular consequences of complement
activation.7,8 This is due to the nature of the distal nerve injury
resulting in severe respiratory paralysis that is incompatible with sur-
vival. Here, we demonstrate that by limiting the doses of AGAb and
complement to an intermediate level, mice still develop a measurable
injury but survive in a humane state, thereby allowing investigation of
immunopathology over extended timepoints. While anti-GD1b anti-
bodies are most typically associated with sensory ataxic forms of GBS
F IGURE 3 Perisynaptic Schwann cells become phagocytic and clear motor nerve terminal debris following anti-ganglioside antibody (AGAb)
and complement-mediated injury. A, Presence of cyan fluorescent protein (CFP) and synapsin staining in control (normal human serum [NHS]) and
injured (Ab and NHS) treated TS preparations, 4 hours following induction of injury (n = 3/group). Injured tissue showed globules of CFP
(expressed in axonal cytoplasm) and synapsin staining within vacuoles in the cell body of the perisynaptic Schwann cell (pSC). Quantification of
axonal component presence in pSC bodies after injury shows significantly higher presence of synapsin and CFP in pSCs after injury than in
control preparations. B, Synapsin and CFP presence following AGAb and NHS-mediated injury in preparations with and without cytochalasin D
(CytD) treatment (n = 3/group). In CytD-treated injury preparations, pSCs do not develop vacuoles and do not demonstrate presence of axon
components. CytD-treated preparations show significantly reduced presence of axon components CFP and synapsin in their cell bodies following
AGAb and NHS-mediated injury to the axon. * = P < .05, ** = P < .01, *** = P < .001, Unpaired t test. Scale bars = 10 μm
CUNNINGHAM ET AL. 149
in humans and rabbits,34,35 we have observed very specific and
restricted binding of anti-GD1b antibody to neuronal membranes,
without any binding to glial cells, in the peripheral motor system of
mice. Indeed, in our ex vivo murine preparations, it is very clearly
observable that distal motor axons are severely affected with no dam-
age to pSC cell membranes. In this sense anti-GD1b antibody can be
used to model motor axonal GBS. While there may be additional sen-
sory deficiencies, we did not investigate these in this study. In human
AMAN, axonal injury has been associated with the infiltration of mac-
rophages at the nodes of Ranvier. In a rabbit model of AMAN, macro-
phages were not associated with complement-disrupted nodes.
Instead, perinodal macrophages were found in the early recovery
phase, suggesting their role may be a response to injury to facilitate
debris clearance, rather than an effector of pathological destruction.6
In our model which exhibits a very limited survival time compared
with human AMAN in which supportive therapy is instituted, AGAbs
primarily and initially affect the distal nerve due to absence of the
blood-nerve barrier at the motor nerve terminal. When we previously
investigated macrophage presence at early timepoints in our severe,
acute AMAN mouse model, no change in neutrophil or macrophage
presence was seen in the vicinity of the injury site.8 Here, we extend
these observations to show that 3 days post-injury, no major differ-
ences in neutrophil or macrophage numbers are seen between NHS-
treated and injured mice either in the total diaphragm by flow cyto-
metry, nor in the area directly surrounding the injury site by immuno-
staining. This may be due to the specific site and type of injury
induced in our model, in which AGAb and complement mediate an
injury that specifically targets the motor nerve terminal and distal
axon. We previously observed that this distal axonal region regener-
ates rapidly, within a few days in mice,36 potentially explaining aspects
of the rapid recovery seen in some cases of AMAN.26 This rapid
regeneration precludes analysis at timepoints usually associated with
immune cell infiltration, in particular macrophages whose presence
peaks between 3 and 7 days post-injury. While injury to the distal
nerve does not appear therefore to require major influence from mac-
rophages and neutrophils, a model of AMAN involving the nerve
roots, another major site of injury in patients, will be useful in deter-
mining the intrinsic and extrinsic cellular consequences of comple-
ment activation by AGAbs. pSCs have been shown to phagocytose
axonal debris at the synapse in other mouse models of distal nerve
injury.21,37 However, until now, longer term studies investigating addi-
tional contributions by immune cells to debris clearance after autoim-
mune distal nerve injury had not been investigated. Our data indicate
that, while we do not rule out participation by these phagocytic cells
in clearance of motor nerve terminal debris, neutrophils and macro-
phages do not appear to play a major role in our model of distal axon
injury at the time points studied. Rather, pSCs may conduct this func-
tion in the same manner as observed in other models of distal axon
injury. In our ex vivo preparations that imitate the in vivo conditions
as far as is practically possible, we demonstrate that pSCs do indeed
phagocytose motor nerve terminal debris following AGAb and
complement-mediated injury and this occurs within 4 hours of com-
plement activation. This rapid phagocytic action of pSCs may explain
the lack of any requirement for recruitment of phagocytic immune
cells to the injury site. This implies that the distal nerve exists within a
niche in which, following injury to the axon, debris clearance rapidly
occurs without outside contribution, allowing for the rapid regenera-
tion of the axon and recovery of function seen in some AMAN
patients.26 This rapid regeneration is further exaggerated in our
mouse model due to the singular and short-lived nature of the injury,
rather than an ongoing immune response as would be seen in patients
whose function is maintained by intensive supportive therapies
unavailable in the mouse.
This study describes a temporally extended mouse model of GBS
which allows survival and recovery from distal nerve injury over a
period of 3 days. This model permits observation of the longer term
consequences of this injury, including recovery dynamics after thera-
peutic intervention and immune cell recruitment. In this model, where
injury occurs primarily at the motor nerve terminal, pSCs are sufficient
to clear axonal debris without any requirement for immune cell infil-
tration over the timepoints studied.
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